Mendus (OM:IMMU BTU) - Stock Price, News & Analysis

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

IMMU BTU Stock Overview

A biopharmaceutical company, develops immunotherapies for the treatment of tumor recurrence and established tumors.

About the company

IMMU BTU fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	5/6
Past Performance	0/6
Financial Health	1/6
Dividends	0/6

Rewards

Earnings are forecast to grow 76.38% per year

Risk Analysis

Makes less than USD$1m in revenue (SEK1M)

Shareholders have been substantially diluted in the past year

Shares are highly illiquid

Does not have a meaningful market cap (SEK268M)

+ 1 more risk

Mendus AB (publ) Competitors

Abliva

OM:ABLI

SEK 249.8m

Active Biotech

OM:ACTI

SEK 106.6m

Kancera

OM:KAN

SEK 228.8m

Isofol Medical

OM:ISOFOL

SEK 638.0m

Price History & Performance

Summary of all time highs, changes and price drops for Mendus
Historical stock prices
Current Share Price	SEK 2.78
52 Week High	SEK 3.99
52 Week Low	SEK 2.65
Beta	0.96
11 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
33 Year Change	n/a
5 Year Change	n/a
Change since IPO	-7.33%

Recent updates

Shareholder Returns

	IMMU BTU	SE Biotechs	SE Market
7D	-7.0%	3.5%	-0.1%
1Y	n/a	37.0%	28.5%

Return vs Industry: Insufficient data to determine how IMMU BTU performed against the Swedish Biotechs industry.

Return vs Market: Insufficient data to determine how IMMU BTU performed against the Swedish Market.

Price Volatility

Is IMMU BTU's price volatile compared to industry and market?
IMMU BTU volatility
IMMU BTU Average Weekly Movement	n/a
Biotechs Industry Average Movement	8.8%
Market Average Movement	5.3%
10% most volatile stocks in SE Market	11.5%
10% least volatile stocks in SE Market	3.2%

Stable Share Price: IMMU BTU's share price has been volatile over the past 3 months.

Volatility Over Time: Insufficient data to determine IMMU BTU's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2002	33	Erik Manting	www.mendus.com

Mendus AB (publ), a biopharmaceutical company, develops immunotherapies and relapse vaccines for the treatment of cancer. Its lead product is DCP-001, which is in Phase II ADVANCE-II clinical trial for the treatment of acute myeloid leukemia; and Phase I ALISON clinical trial for the treatment of ovarian cancers. The company’s products also develops ilixadencel, which is in Phase II clinical trial for the treatment of kidney cancer; and Phase II clinical trial to treat gastrointestinal stromal tumors.

Mendus AB (publ) Fundamentals Summary

How do Mendus's earnings and revenue compare to its market cap?
IMMU BTU fundamental statistics
Market cap	SEK 268.23m
Earnings (TTM)	-SEK 141.37m
Revenue (TTM)	SEK 1.37m

195.8x

P/S Ratio

-1.9x

P/E Ratio

Is IMMU BTU overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
IMMU BTU income statement (TTM)
Revenue	SEK 1.37m
Cost of Revenue	SEK 0
Gross Profit	SEK 1.37m
Other Expenses	SEK 142.74m
Earnings	-SEK 141.37m

Last Reported Earnings

Mar 31, 2023

Next Earnings Date

Aug 29, 2023

Earnings per share (EPS)	-0.21
Gross Margin	100.00%
Net Profit Margin	-10,319.12%
Debt/Equity Ratio	17.1%

How did IMMU BTU perform over the long term?

See historical performance and comparison

Mendus OM:IMMU BTU Stock Report